Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients

Yan Feng, Guangyun Mao, Xiaowei Ren, Houxun Xing, Genfu Tang, Qiang Li, Xueqi Li, Lirong Sun, Jinqui Yang, Weiqing Ma, Xiaobin Wang, Xiping Xu

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - The purpose of this study was to investigate whether genetic variants could influence the antidiabetic efficacy of gliclazide in type 2 diabetic patients. RESEARCH DESIGN AND METHODS- A total of 1,268 type 2 diabetic patients whose diabetes was diagnosed within the past 5 years and who had no recent hypoglycemic treatment were enrolled from 23 hospitals in China. All of the patients were treated with gliclazide for 8 weeks. Fasting and oral glucose tolerance test 2-h plasma glucose, fasting insulin, and A1C were measured at baseline and after 8 weeks of treatment. We used two independent cohorts to test the associations of 25 single nuclear polymorphisms in 11 candidate genes with the antidiabetic efficacy of gliclazide. A general linear regression model was used to test the association with adjustment for important covariates. RESULTS- After 8 weeks of gliclazide therapy, mean fasting plasma glucose (FPG) was reduced from 11.1 mmol/1 at baseline to 7.7 mmol/1. In cohort 1, we genotyped all 25 SNPs (n = 661) and found that Serl369Ala of the ABCC8 gene and rs5210 of the KCNJ11 gene were significantly associated with decreases in FPG (P = 0.002). We further genotyped Serl369Ala in cohort 2 (n = 607) and confirmed the association identified in cohort 1. In the pooled analysis, compared with subjects with the Ser/Ser genotype, subjects with the Ala/Ala genotype had a 7.7% greater decrease in FPG (P <0.001), an 11.9% greater decrease in 2-h plasma glucose (P = 0.003), and a 3.5% greater decrease in A1C (P = 0.06) after 8 weeks of treatment with gliclazide. CONCLUSIONS- In two independent cohorts of Chinese type 2 diabetic patients, we found consistent evidence that the Serl369Ala variant in the ABCC8 gene can influence the antidiabetic efficacy of gliclazide.

Original languageEnglish (US)
Pages (from-to)1939-1944
Number of pages6
JournalDiabetes Care
Volume31
Issue number10
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Sulfonylurea Receptors
Gliclazide
Hypoglycemic Agents
Fasting
Glucose
Genes
Linear Models
Genotype
Therapeutics
Glucose Tolerance Test
Single Nucleotide Polymorphism
China
Research Design
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. / Feng, Yan; Mao, Guangyun; Ren, Xiaowei; Xing, Houxun; Tang, Genfu; Li, Qiang; Li, Xueqi; Sun, Lirong; Yang, Jinqui; Ma, Weiqing; Wang, Xiaobin; Xu, Xiping.

In: Diabetes Care, Vol. 31, No. 10, 10.2008, p. 1939-1944.

Research output: Contribution to journalArticle

Feng, Yan ; Mao, Guangyun ; Ren, Xiaowei ; Xing, Houxun ; Tang, Genfu ; Li, Qiang ; Li, Xueqi ; Sun, Lirong ; Yang, Jinqui ; Ma, Weiqing ; Wang, Xiaobin ; Xu, Xiping. / Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. In: Diabetes Care. 2008 ; Vol. 31, No. 10. pp. 1939-1944.
@article{e306438f94104f049742b7e5504abd07,
title = "Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients",
abstract = "OBJECTIVE - The purpose of this study was to investigate whether genetic variants could influence the antidiabetic efficacy of gliclazide in type 2 diabetic patients. RESEARCH DESIGN AND METHODS- A total of 1,268 type 2 diabetic patients whose diabetes was diagnosed within the past 5 years and who had no recent hypoglycemic treatment were enrolled from 23 hospitals in China. All of the patients were treated with gliclazide for 8 weeks. Fasting and oral glucose tolerance test 2-h plasma glucose, fasting insulin, and A1C were measured at baseline and after 8 weeks of treatment. We used two independent cohorts to test the associations of 25 single nuclear polymorphisms in 11 candidate genes with the antidiabetic efficacy of gliclazide. A general linear regression model was used to test the association with adjustment for important covariates. RESULTS- After 8 weeks of gliclazide therapy, mean fasting plasma glucose (FPG) was reduced from 11.1 mmol/1 at baseline to 7.7 mmol/1. In cohort 1, we genotyped all 25 SNPs (n = 661) and found that Serl369Ala of the ABCC8 gene and rs5210 of the KCNJ11 gene were significantly associated with decreases in FPG (P = 0.002). We further genotyped Serl369Ala in cohort 2 (n = 607) and confirmed the association identified in cohort 1. In the pooled analysis, compared with subjects with the Ser/Ser genotype, subjects with the Ala/Ala genotype had a 7.7{\%} greater decrease in FPG (P <0.001), an 11.9{\%} greater decrease in 2-h plasma glucose (P = 0.003), and a 3.5{\%} greater decrease in A1C (P = 0.06) after 8 weeks of treatment with gliclazide. CONCLUSIONS- In two independent cohorts of Chinese type 2 diabetic patients, we found consistent evidence that the Serl369Ala variant in the ABCC8 gene can influence the antidiabetic efficacy of gliclazide.",
author = "Yan Feng and Guangyun Mao and Xiaowei Ren and Houxun Xing and Genfu Tang and Qiang Li and Xueqi Li and Lirong Sun and Jinqui Yang and Weiqing Ma and Xiaobin Wang and Xiping Xu",
year = "2008",
month = "10",
doi = "10.2337/dc07-2248",
language = "English (US)",
volume = "31",
pages = "1939--1944",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients

AU - Feng, Yan

AU - Mao, Guangyun

AU - Ren, Xiaowei

AU - Xing, Houxun

AU - Tang, Genfu

AU - Li, Qiang

AU - Li, Xueqi

AU - Sun, Lirong

AU - Yang, Jinqui

AU - Ma, Weiqing

AU - Wang, Xiaobin

AU - Xu, Xiping

PY - 2008/10

Y1 - 2008/10

N2 - OBJECTIVE - The purpose of this study was to investigate whether genetic variants could influence the antidiabetic efficacy of gliclazide in type 2 diabetic patients. RESEARCH DESIGN AND METHODS- A total of 1,268 type 2 diabetic patients whose diabetes was diagnosed within the past 5 years and who had no recent hypoglycemic treatment were enrolled from 23 hospitals in China. All of the patients were treated with gliclazide for 8 weeks. Fasting and oral glucose tolerance test 2-h plasma glucose, fasting insulin, and A1C were measured at baseline and after 8 weeks of treatment. We used two independent cohorts to test the associations of 25 single nuclear polymorphisms in 11 candidate genes with the antidiabetic efficacy of gliclazide. A general linear regression model was used to test the association with adjustment for important covariates. RESULTS- After 8 weeks of gliclazide therapy, mean fasting plasma glucose (FPG) was reduced from 11.1 mmol/1 at baseline to 7.7 mmol/1. In cohort 1, we genotyped all 25 SNPs (n = 661) and found that Serl369Ala of the ABCC8 gene and rs5210 of the KCNJ11 gene were significantly associated with decreases in FPG (P = 0.002). We further genotyped Serl369Ala in cohort 2 (n = 607) and confirmed the association identified in cohort 1. In the pooled analysis, compared with subjects with the Ser/Ser genotype, subjects with the Ala/Ala genotype had a 7.7% greater decrease in FPG (P <0.001), an 11.9% greater decrease in 2-h plasma glucose (P = 0.003), and a 3.5% greater decrease in A1C (P = 0.06) after 8 weeks of treatment with gliclazide. CONCLUSIONS- In two independent cohorts of Chinese type 2 diabetic patients, we found consistent evidence that the Serl369Ala variant in the ABCC8 gene can influence the antidiabetic efficacy of gliclazide.

AB - OBJECTIVE - The purpose of this study was to investigate whether genetic variants could influence the antidiabetic efficacy of gliclazide in type 2 diabetic patients. RESEARCH DESIGN AND METHODS- A total of 1,268 type 2 diabetic patients whose diabetes was diagnosed within the past 5 years and who had no recent hypoglycemic treatment were enrolled from 23 hospitals in China. All of the patients were treated with gliclazide for 8 weeks. Fasting and oral glucose tolerance test 2-h plasma glucose, fasting insulin, and A1C were measured at baseline and after 8 weeks of treatment. We used two independent cohorts to test the associations of 25 single nuclear polymorphisms in 11 candidate genes with the antidiabetic efficacy of gliclazide. A general linear regression model was used to test the association with adjustment for important covariates. RESULTS- After 8 weeks of gliclazide therapy, mean fasting plasma glucose (FPG) was reduced from 11.1 mmol/1 at baseline to 7.7 mmol/1. In cohort 1, we genotyped all 25 SNPs (n = 661) and found that Serl369Ala of the ABCC8 gene and rs5210 of the KCNJ11 gene were significantly associated with decreases in FPG (P = 0.002). We further genotyped Serl369Ala in cohort 2 (n = 607) and confirmed the association identified in cohort 1. In the pooled analysis, compared with subjects with the Ser/Ser genotype, subjects with the Ala/Ala genotype had a 7.7% greater decrease in FPG (P <0.001), an 11.9% greater decrease in 2-h plasma glucose (P = 0.003), and a 3.5% greater decrease in A1C (P = 0.06) after 8 weeks of treatment with gliclazide. CONCLUSIONS- In two independent cohorts of Chinese type 2 diabetic patients, we found consistent evidence that the Serl369Ala variant in the ABCC8 gene can influence the antidiabetic efficacy of gliclazide.

UR - http://www.scopus.com/inward/record.url?scp=56149106823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56149106823&partnerID=8YFLogxK

U2 - 10.2337/dc07-2248

DO - 10.2337/dc07-2248

M3 - Article

C2 - 18599530

AN - SCOPUS:56149106823

VL - 31

SP - 1939

EP - 1944

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -